F-star Therapeutics EBIT

F-star Therapeutics (FSTX) currently reports a EBIT of $-37M as of September 2022. That compares with $-45M in the prior-year period — up 17.7% year over year. That is below the Healthcare sector average of $99B. Use the charts on this page to explore F-star Therapeutics's EBIT history and peer comparisons.

F-star Therapeutics's EBIT increased from $-45M to $-37M — a 17.7% year-over-year increase (period ending September 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

F-star Therapeutics's EBIT of $-37M is lower than the Healthcare sector average of $99B. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

F-star Therapeutics reported $-37M in EBIT as of September 2022. That compares with $-45M in the prior-year period — up 17.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-37M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $99B. From there, open related valuation or income-statement pages for F-star Therapeutics, and consider following FSTX for alerts when major investors trade the stock.